RPI ID:
2023-007-601

Innovation Summary:
This technology describes therapeutic systems and methods using sulfated glycosaminoglycans (GAGs) and GAG analogs to treat or prevent monkeypox virus (Mpox) infections. The compounds interfere with viral attachment and entry mechanisms, reducing infectivity. The approach is designed for topical or systemic administration and may be used prophylactically or therapeutically. It supports rapid response to emerging viral threats using biomolecular inhibition strategies.

Challenges / Opportunities:
Current Mpox treatments are limited and primarily supportive. This invention addresses the need for targeted antiviral therapies that can be deployed quickly. It opens opportunities for broad-spectrum antiviral development and public health preparedness. The method also supports formulation into gels, creams, or injectables for flexible delivery.

Key Benefits / Advantages:
✔ Targets viral entry mechanisms
✔ Applicable for prevention and treatment
✔ Supports multiple delivery formats
✔ Rapid-response antiviral strategy

Applications:
• Antiviral therapeutics for Mpox and related viruses

Keywords:
Monkeypox, Mpox, glycosaminoglycans, antiviral therapy, viral inhibition

Intellectual Property:
US 18/906669, Published October 4, 2024